poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Shattuck Labs, Lowers Price Target to $14

Aug 11, 2026, 4:13 PMBenzinga Newsdesk

HC Wainwright & Co. analyst Joseph Pantginis maintains Shattuck Labs (NASDAQ:STTK) with a Buy and lowers the price target from $18 to $14.

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

STTK
Source
benzinga
Observed
Aug 11, 2026, 4:13 PM
Checked
Aug 11, 2026, 4:13 PM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Aug 24, 2026, 10:03 PMEric Volkman

    What Shattuck Labs Stock Topped the Market on Monday

    Shattuck Labs (STTK) gained nearly 5% on Monday following positive analyst coverage from two firms. TD Cowen initiated a buy rating while Raymond James issued a strong buy with an $18 price target (more than double the $7.90 closing price). The optimism centers on the company's lead drug candidate SL-325, a first-in-class autoimmune and inflammatory disease treatment currently in Phase 2b clinical testing for inflammatory bowel disease, with analysts estimating a $20+ billion addressable market.

    Read original at the-motley-fool
    STTK